Trial Profile
Phase II Study of Fulvestrant (Faslodex) in Androgen Independent Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 24 Jan 2013 Planned end date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Feb 2012 Planned End Date changed from 1 Jun 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.